ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass., Mar 01, 2010 (BUSINESS WIRE) -- ImmunoGen, Inc. (Nasdaq: IMGN) announced today that management will participate in two upcoming investor conferences with live webcasts.
RBC Capital Markets Healthcare Conference, New York Palace Hotel, New York, NY
Gregory Perry, Senior Vice President and Chief Financial Officer, will participate on the panel, "Building a Proprietary and Partnered Pipeline of Antibodies," on Wednesday, March 3, 2010, at 2:05 p.m. EST. This panel discussion can be accessed live through the "Investor Information" section of the Company's website, http://www.immunogen.com. An archive of the webcast will be available at the same location until March 10, 2010.
Cowen and Company 30th Annual Health Care Conference, The Boston Marriott Copley Place, Boston, MA
Daniel Junius, President and Chief Executive Officer, will present at the 30th Annual Cowen Health Care Conference at 4:30 pm EST on March 9, 2010. This webcast can also be accessed live at http://www.immunogen.com; its archive will be available until March 16, 2010.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Targeted Antibody Payload (TAP) technology uses antibodies to deliver one of ImmunoGen's cancer-cell killing agents specifically to tumor targets. In addition to the Company's product pipeline, compounds utilizing the TAP technology are in clinical testing through ImmunoGen's collaborations with Genentech (a wholly owned member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. The most advanced compound, trastuzumab-DM1 (T-DM1), is in Phase III testing being conducted by Genentech and Roche. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen. More information about ImmunoGen can be found at http://www.immunogen.com.
SOURCE: ImmunoGen, Inc.
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and
Corporate Communications
info@immunogen.com
